Sign up to save your podcasts
Or
Share Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice.
Episode Highlights:
• Understanding the current standard of care for AML, including diagnosis and risk stratification.
• The importance of molecular profiling and how it influences treatment decisions.
• A detailed discussion on induction chemotherapy options, including the classic 7+3 regimen and CPX351 for therapy-related AML.
• Insights into the use of hypomethylating agents combined with venetoclax for patients unfit for intensive chemotherapy.
• The role of targeted therapies in both upfront treatment and relapsed/refractory settings.
• Key considerations for managing side effects, including cytopenias and infections.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
YouTube: https://youtu.be/gbgRbrjHxmQ
Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients.
Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice.
Episode Highlights:
• Understanding the current standard of care for AML, including diagnosis and risk stratification.
• The importance of molecular profiling and how it influences treatment decisions.
• A detailed discussion on induction chemotherapy options, including the classic 7+3 regimen and CPX351 for therapy-related AML.
• Insights into the use of hypomethylating agents combined with venetoclax for patients unfit for intensive chemotherapy.
• The role of targeted therapies in both upfront treatment and relapsed/refractory settings.
• Key considerations for managing side effects, including cytopenias and infections.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
YouTube: https://youtu.be/gbgRbrjHxmQ
Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients.
Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
295 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,358 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners